Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 115-120

  Meyer, Ralph M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Chemotherapy; Hodgkin's lymphoma; Late effects; Limited stage; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE; ABVD PROTOCOL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; SECOND CANCER; TREATMENT OUTCOME; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 21044458416     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. LONGO DL. Hodgkin disease: the sword of Damocles resheathed. Blood 2004;104:3418.
2. MEYER RM, AMBINDER RF, STROOBANTS S. Hodgkin' lymphoma: evolving concepts with implications for practice. Hematology (Am Soc Hematol Educ Program) 2004;184-202.
3. MEYER RM, KOUROUKIS CT. Understanding outcome measures. Evidenced-based Oncol 2001;2:172-176.
4. PRESS OW, LEBLANC M, LICHTER AS, GROGAN TM, UNGER JM, WASSERMAN TH, GAYNOR ER, PETERSON BA, MILLER TP, FISHER RI. Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19:4238-4244.
5. HAGENBEEK A, EGHBALI H, FERMÉ C, et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin's disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 2000;96:575a.
6. SIEBER M, FRANKLIN J, TESCH H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 2002;100:93a.
7. MEYER RM, GOSPODAROWICZ MK, CONNORS JM, et al. A randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 2005 (in press).
8. DIEHL V, STEIN H, HUMMEL M, ZOLLINGER R, CONNORS JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003;225-247.
9. CARDE P, HAGENBEEK A, HAYAT M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2225-2272.
10. SPECHT L, GRAY RG, CLARKE MJ, PETO R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-843.
11. CANELLOS GP, ANDERSON JR, PROPERT KJ, NISSEN N, COOPER MR, HENDERSON ES, GREEN MR, GOTTLIEB A, PETERSON BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
12. DUGGAN DB, PETRONI GR, JOHNSON JL, GLICK JH, FISHER RI, CONNORS JM, CANELLOS GP, PETERSON BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614.
13. HENRY-AMAR M, AEPPLI DM, ANDERSON J, et al. Long term survival and study of causes of death. In: SOMERS R, HENRY-AMAR M, MEERWALDT JK, CARDE P, eds. Treatment Strategy in Hodgkin's Disease. London: John Libbey and Co., 1990:381-418.
14. DORES GM, METAYER C, CURTIS RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-3494.
15. SWERDLOW AJ, BARBER JA, HUDSON GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
16. NG AK, BERNARDO MVP, WELLER E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-1996.
17. van LEEUWEN FE, KLOKMAN WJ, VAN'T VEER MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adult. J Clin Oncol 2000;18:487-497.
18. METAYER C, LYNCH CF, CLARKE EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18:2435-2443.
19. BHATIA S, ROBISON LL, OBERLIN O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
20. HULL MC, MORRIS CG, PEPINE CJ, MENDENHALL NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003;290:2831-2837.
21. REINDERS JG, HEIJMEN BJ, OLOFSEN-VAN ACHT MJ, van PUTTEN WL, LEVENDAG PC. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999;51:35-42.
22. ERIKSSON F, GAGLIARDI G, LIEDBERG A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model. Radiother Oncol 2000;55:153-162.
23. LEE CK, AEPPLI D, NIERENGARTEN ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000;48:169-179.
24. LOEFFLER M, BROSTEANU O, HASENCLEVER D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998;16:818-829.
25. ALEMAN BM, RAEMAEKERS JM, TIRELLI U, et al. Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. N. Engl J Med 2003;348:2396-2406.
26. LONGO DL, GLATSTEIN E, DUFFEY PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 1991;9:906-917.
27. BITI GP, CIMINO G, CARTONI C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992;10:378-382.
28. PAVLOVSKY S, MASCHIO M, SANTARELLI MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988;80:1466-1473.
29. NACHMAN JB, SPOSTO R, HERZOG P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
30. STRAUS DJ, PORTLOCK CS, QIN J, MYERS J, ZELENETZ AD, MOSKOWITZ C, NOY A, GOY A, YAHALOM J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489.
31. LASKAR S, GUPTA T, VIMAL S, MUCKADEN MA, SAIKIA TK, PAI SK, NARESH KN, DINSHAW KA. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-68.
32. THOMAS J, FERME C, NOORDIJK EM, RIEUX C, HENNEQUIN C, LYBEERT MLM, GIRINSKY T, VAN T, MEER MB, HENRY-AMAR M. Six cycles of EBVP followed by 36 Gy involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: the EORTC-GELA strategy in 771 patients. Eur J Haematol 2004;73(Suppl. 64):40 (abstract).
33. BURGERS JMV, TIRELLI U, MONCONDUIT M, et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF', 'H7-F' and 'H7-U'. Int J Rad Oncol Biol Phys 1997;39(Suppl. 1):173 (abstract).
34. DIEHL V, BRILLANT C, ENGERT A, et al. Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin's Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. Blood 2004;104:368a (abstract).